Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia

Abstract

Purpose of reviewThe treatment of hypertriglyceridemia (HTG) with v-3 fatty acid preparations adds a novel therapy to reduce cardiovascular disease. This review examines the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid on lipoproteins and the cardioprotective effects in HTG. Recent findingsThe evidence that v-3 fatty acid therapy at prescription strength is effective and safe at lowering triglyceride levels is growing. Although EPA/docosahexaenoic acid formulations did lower triglyceride levels, an increase in low-density lipoproteins was observed and outcome data were mixed. More recent trials have shown that decreased levels of low-density lipoprotein can be achieved with EPA preparations. Although the cardiovascular outcomes data are not fully available, meta-analysis of available data reports protection against vascular disease. SummaryThe addition of v-3 fatty acid treatment should be considered in patients with severe HTG as well as high-risk patients for atherosclerotic disease. Emerging data are supportive, but long-term outcome studies are still underway.

Epoxide metabolites of arachidonate and docosahexaenoate function conversely in acute kidney injury involved in GSK3β signaling

“…The epoxide metabolites of ω-3 PUFAs (e.g., EDPs) were reported sporadically regarding their biological functions although ω-3 PUFAs, such as DHA and eicosapentaenoic acid (EPA), as well as DHA-and EPA-enriched foods, have been reported and reviewed extensively to be antiinflammatory, cardio-protective, reno-protective, and tumor inhibitory (10,(19)(20)(21)(22)(23)(24). Sharma et al (12) reported recently that 19 (20)-EDP significantly reduced renal fibrosis in a murine model of unilateral ureteral obstruction (UUO)-induced uremia.…”

Lipidomics Approach in High-Fat-Diet-Induced Atherosclerosis Dyslipidemia Hamsters: Alleviation Using Ether-Phospholipids in Sea Urchin

“…7 Dietary intervention offers an alternative with potential benefits over currently available treatments for atherosclerotic dyslipidemia. 8 Several animal studies have demonstrated that seafood and marine byproducts exert strong cholesterol-lowering and lipid-regulating effects. Lamaziere et al 9 found that prolonged feeding with eicosapentaenoic acid (EPA)-and docosahexaenoic-acid-enriched fish oil decreases hepatic fat levels and ameliorates non-alcoholic fatty liver disease prognosis.…”

“…Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD), although contrasting observations have been reported. , Statin therapy is effective for lowering low-density lipoprotein (LDL) levels; however, side effects, including central nervous system complaints, have been reported . Dietary intervention offers an alternative with potential benefits over currently available treatments for atherosclerotic dyslipidemia . Several animal studies have demonstrated that seafood and marine byproducts exert strong cholesterol-lowering and lipid-regulating effects.…”

Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study

“…Importantly, the effect of omega-3 fatty acids on CV outcomes is unknown, but two randomized outcome trials, REDUCE-IT and STRENGTH, are assessing additional risk reduction when statins are combined with omega-3 fatty acid therapy. 10,11 In general, treatment with 2-4 g of a prescription-grade omega-3 fatty acid formulation, containing mainly EPA and/or DHA, reduces serum TG levels by approximately 30%. 3,5 Omega-3 fatty acids reduce serum TG levels by decreasing VLDL production rates, while VLDL clearance rates are less consistently affected.…”